Reisz Edwin C. sold $575K of AVAH

Reisz Edwin C. (Chief Administrative Officer) sold 50,000 shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $11.50 ($0.58M total) on 2026-08-20.

Original reporting
SEC EDGAR · Reisz Edwin C.
Published Aug 24, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVAH
Neutral
high confidence
Mentioned
$AVAH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHNeutralLow
01

Why it matters

A modest insider sell by a senior officer may signal slight downside pressure but the amount is small relative to total holdings.

02

Market read

Limited short‑term impact; price likely unchanged.

03

Timing

filed Aug 24 2026

Relevance 5/10Novelty 4/10Timing: filed Aug 24 2026
Company-level read

Ticker impact

$AVAHNeutralHigh confidence
Context

Chief Administrative Officer Reisz Edwin C. sold 50,000 shares for $575,000 on Aug 20, 2026 (Form 4 filing).

Expected impact

Limited short‑term impact; price likely unchanged.

Evidence & confidence

The sale represents less than 0.04% of the insider's remaining holdings and is below material thresholds for market reaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.